Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

Search results for decitabine in root_modifications_agentModifications_agentSubstance_refPname (approximate match)

Showing 1 - 1 of 1 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

AUTOLOGOUS EX VIVO EXPANDED CD4+-ENRICHED LEUKOCYTES TREATED WITH THE DE-METHYLATING AGENT 5-AZA-DEOXYCYTIDINE

B2NUS89036

Status:

Investigational

Source:

NCT02799238: Phase 2 Interventional Completed Glioblastoma

(2016)

Source URL:

https://clinicaltrials.gov/ct2/show/NCT02799238

Class:

STRUCTURALLY DIVERSE

Structurally Diverse

AUTOLOGOUS EX VIVO EXPANDED CD4+-ENRICHED LEUKOCYTES TREATED WITH THE DE-METHYLATING AGENT 5-AZA-DEOXYCYTIDINE

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1